Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug...To view the full article, register now.
Already a subscriber? Click here to view full article